KURA
A little spark for Kura
Kura Oncology just gave Wall Street something to chew on: preliminary data from its FIT-001 study showed darlifarnib, when paired with cabozantinib, was doing more than just showing up in clear cell renal cell carcinoma. The stock popped 9% as traders reacted to the early signal.
The numbers that got people leaning in
In a subset of 16 patients who’d already been treated with cabozantinib, the combo posted a 44% objective response rate and a 94% disease control rate. Even better for the bulls, tumor shrinkage was seen in 75% of patients, and six people were still on treatment at the data cutoff.
Why investors care
Biotech is basically a long game of "show me something that works." Early efficacy in a heavily pretreated cancer population can matter a lot because it suggests the drug combo may still have legs in a setting where options are limited and expectations are usually pretty grim.
That said, this is still a small subset analysis, not a victory lap. The next question is whether Kura can turn this into a cleaner, broader story with more patients and more durability. Big picture: today’s pop says investors like the setup, but the stock will need follow-through data before anyone starts writing the sequel.